Interview with Odnir Finotti, Executive President, Pró Genéricos
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Address: Rua Alvorada, 1280
CEP : 04550-004
Rua Alvorada, 1280 CEP : 04550-004 São Paulo – SP,Brazil
Tel: (11) 3897-9767
Web: http://www.progenericos.org.br/
Founded in January 2001, the Brazilian Association of Generic Drugs – Pró Genéricos brings together leading laboratories working in the production and marketing generic drugs in the country.
Pró Genéricos is a nonprofit entity whose main mission is to contribute to the improvement of access to medicines in Brazil through the consolidation and expansion of the generics market.
Together, the members of the Pro Generic constitutes around 90% of sales in the generics business in the country. Pro Generic connects various sectors of society, institutions of public and private channels with the actions of its members, giving substance to public debate on issues relevant to the health sector and the development of the pharmaceutical industry in the country .
Since September 2005, Pró Genéricos has been part of the Generic IGPA (International Generic Pharmaceutical Alliance), as an observer. Founded in March 1997, the IGPA is an international organization that seeks to ensure consumer access to medicines that meet quality and economy.
Industry Association.
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
See our Cookie Privacy Policy Here
